Morgan Stanley analyst Michael Ulz assumed coverage of Rhythm Pharmaceuticals (RYTM) with an Overweight rating and $72 price target The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback